Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Motor neuropathy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    73 result(s) found for: Motor neuropathy. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2008-005748-18 Sponsor Protocol Number: SN07NE080 Start Date*: 2009-01-02
    Sponsor Name:Greater Glasgow and Clyde NHS Board and The University Of Glasgow
    Full Title: SAFETY AND TOLERABILITY OF ECULIZUMAB IN THE TREATMENT OF MULTIFOCAL MOTOR NEUROPATHY: AN OPEN LABEL STUDY
    Medical condition: Multifocal motor neuropathy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065579 Multifocal motor neuropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-002827-14 Sponsor Protocol Number: TreatSPG11 Start Date*: 2021-01-19
    Sponsor Name:IRCCS Fondazione Stella Maris
    Full Title: Phase 2 pharmacological experimental study to test the safety of miglustat in subjects with hereditary spastic paraplegia type 11
    Medical condition: Spastic paraparesis type 11 (SPG11), caused by mutations in spatacsin protein, is characterized by the association of peripheral neuropathy, parkinsonism, ataxia, cognitive impairment, hypotrophy o...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10019903 Hereditary spastic paraplegia PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-012073-34 Sponsor Protocol Number: R0000063 Start Date*: 2009-07-08
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: Botulinum toxin for treating calf muscle spasticity in Hereditary Spastic Paraparesis (HSP): functional effects on dynamic balance and gait
    Medical condition: Subjects with hereditary spastic paraparesis (HSP)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019903 Hereditary spastic paraplegia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-013841-27 Sponsor Protocol Number: 160604 Start Date*: 2009-12-17
    Sponsor Name:Baxter Innovations GmbH
    Full Title: A Randomized, Double-Blind, Placebo Controlled, Cross-over Study of the Effectiveness of Immune Globulin Intravenous (Human), 10% (IGIV, 10%) for the Treatment of Multofocl Motor Neuropathy
    Medical condition: Multifocal motor neuropathy
    Disease: Version SOC Term Classification Code Term Level
    12.0 10065579 Multifocal motor neuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-004998-32 Sponsor Protocol Number: ARGX-117-2003 Start Date*: 2022-12-19
    Sponsor Name:argenx BV
    Full Title: A Long-Term Extension of the ARGX-117-2002 Trial to Evaluate the Long-term Safety and Tolerabillity, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults with Mult...
    Medical condition: Multifocal Motor Neuropathy
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10065579 Multifocal motor neuropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Trial now transitioned) BE (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-000710-37 Sponsor Protocol Number: ZLB06_006CR Start Date*: 2007-12-10
    Sponsor Name:CSL Behring AG
    Full Title: A multicentre study of subcutaneous immunoglobulin in patients with Multifocal Motor Neuropathy (MMN)
    Medical condition: Patients with multifocal motor neuropathy, who are treated successful with IVIG and had a stable IVIG treatment schedule for at least 12 weeks prior to screening.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065579 Multifocal motor neuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-000398-21 Sponsor Protocol Number: ESTEVE-SIGM-202 Start Date*: 2012-06-21
    Sponsor Name:Laboratorios del Dr. Esteve, S.A.
    Full Title: A proof-of-concept phase 2, randomized, placebo-controlled, double blind, multicentre clinical trial in 2 parallel groups to evaluate the efficacy and safety of E-52862 for reducing the incidence a...
    Medical condition: OXL-induced chronic neuropathy.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10029350 Neurotoxicity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2012-001995-12 Sponsor Protocol Number: I10E-0901 Start Date*: 2015-05-19
    Sponsor Name:LFB BIOTECHNOLOGIES
    Full Title: A European, randomised, double-blind, active comparator-controlled, cross-over, efficacy and safety study of a new 10% ready-to-use liquid human intravenous immunoglobulin (I10E) versus Kiovig® in ...
    Medical condition: Multifocal motor neuropathy (MMN)
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029205 - Nervous system disorders 10065579 Multifocal motor neuropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) GB (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-022046-25 Sponsor Protocol Number: Zellweger Start Date*: Information not available in EudraCT
    Sponsor Name:Department of Pediatric Gastroenterology, Academic Medical Centre
    Full Title: Cholic acid treatment in Peroxisomal Biogenesis Disorders (Zellweger spectrum): biochemical and clinical effects.
    Medical condition: Peroxisomal biogenesis disorder Synonym: Zellweger spectrum disorder This syndrome encompasses a spectrum of severity in symptoms Previously the disorder was subdivided into three disorders based...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10053706 Zellweger syndrome LLT
    12.1 10038275 Refsum's disease LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003054-16 Sponsor Protocol Number: DDZ-BOND-2017 Start Date*: 2018-07-27
    Sponsor Name:Wörwag Pharma GmbH & co. KG
    Full Title: Randomized double-blind, placebo-controlled parallel group study over 12 months to assess the effects of treatment with benfotiamine on morphometric, neurophysiological, and clinical measures in ty...
    Medical condition: diabetic polyneuropathy
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10012685 Diabetic polyneuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003302-50 Sponsor Protocol Number: ARGX-117-2002 Start Date*: 2022-01-31
    Sponsor Name:argenx BV
    Full Title: A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicit...
    Medical condition: Multifocal Motor Neuropathy
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10065579 Multifocal motor neuropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) DE (Completed) BE (Completed) IT (Completed) PL (Completed) AT (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003453-18 Sponsor Protocol Number: RH-2015-200 Start Date*: 2015-11-25
    Sponsor Name:Rigshospitalet
    Full Title: A Randomized, Single-blinded, Cross-over Study investigating the Non-inferiority of Efficacy and Safety of HyQvia in comparison with Conventional Subcutaneous Ig Therapy in Multifocal Motor Neuropa...
    Medical condition: Multifocal Motor Neuropathy (MMN)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10064135 Polyneuropathy chronic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-001246-17 Sponsor Protocol Number: CBX129801-DN-201 Start Date*: 2013-05-28
    Sponsor Name:Cebix Incorporated
    Full Title: A Phase 2b, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of CBX129801 (Ersatta™), Long-Acting Synthetic C-Peptide, in Type 1 Diabetes Mellitus Subjects wit...
    Medical condition: Mild to moderate diabetic peripheral neuropathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002523-42 Sponsor Protocol Number: D5680C00002 Start Date*: 2018-10-22
    Sponsor Name:AstraZeneca AB
    Full Title: A randomised, double-blind, placebo-controlled, dose-response study of the efficacy and safety of MEDI7352 in subjects with painful diabetic neuropathy
    Medical condition: Painful diabetic neuropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10012680 Diabetic neuropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended) PL (Prematurely Ended) HU (Prematurely Ended) DK (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2012-003197-57 Sponsor Protocol Number: A0081181 Start Date*: 2012-11-09
    Sponsor Name:Pfizer Worldwide Research and Development
    Full Title: A MULTIPLE DOSE PHARMACOKINETIC OPEN-LABEL STUDY OF PREGABALIN (LYRICA) IN HEALTHY LACTATING WOMEN
    Medical condition: neuropathic pain associated with diabetic peripheral neuropathy postherpetic neuralgia neuropathic pain related to spinal cord injury (US), fibromyalgia (US, JP) treatment of central and periphe...
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029205 - Nervous system disorders 10028005 Motor peripheral neuropathy LLT
    15.1 10029205 - Nervous system disorders 10054095 Neuropathic pain LLT
    15.1 10029205 - Nervous system disorders 10036376 Post herpetic neuralgia PT
    15.1 10029205 - Nervous system disorders 10067547 Diabetic peripheral neuropathic pain LLT
    15.1 10022117 - Injury, poisoning and procedural complications 10041552 Spinal cord injury PT
    15.1 10037175 - Psychiatric disorders 10018075 Generalised anxiety disorder PT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-006488-22 Sponsor Protocol Number: E2007-G000-227 Start Date*: 2007-10-03
    Sponsor Name:Eisai Limited
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Trial to Evaluate the Efficacy and Safety of E2007 in Patients with Painful Diabetic Neuropathy
    Medical condition: Painful Diabetic Neuropathy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012680 Diabetic neuropathy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) LT (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-000585-30 Sponsor Protocol Number: I16016 Start Date*: 2017-12-13
    Sponsor Name:CHU de Limoges
    Full Title: Pilot study, single-blind, candesartan versus usual care of peripheral neuropathy development induced by vincristine (PNIV) in patients treated for lymphoma B.
    Medical condition: peripheral neuropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    20.0 10029205 - Nervous system disorders 10029331 Neuropathy peripheral PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-001218-26 Sponsor Protocol Number: TRO19622 CL E Q 1204-1 Start Date*: 2008-06-19
    Sponsor Name:TROPHOS SA
    Full Title: A double blind, placebo controlled study of the effect of 330mg QD of TRO19622 in the treatment of Chemotherapy Induced Peripheral Neuropathy.
    Medical condition: Symptoms of chemotherapy induced peripheral neuropathy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036109 Polyneuropathy due to drugs LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-005326-23 Sponsor Protocol Number: PHRC-K2020PEZET Start Date*: 2022-01-24
    Sponsor Name:CHU de Clermont-Ferrand
    Full Title: Evaluation of the efficacy of donepezil in the treatment of oxaliplatin-induced peripheral neuropathy: proof of concept study
    Medical condition: Oxaliplatine-induced peripheral neuropathy
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002810-15 Sponsor Protocol Number: CHUB-Neuro-ENMG-MS Start Date*: 2021-06-25
    Sponsor Name:CHU Brugmann
    Full Title: Peripheral neuropathy as potential side effect in patients with multiple sclerosis treated with teriflunomide.
    Medical condition: Multiple sclerosis, treated with teriflunomide
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 18 10:27:17 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA